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ABSTRACT
Oral squamous cell carcinoma (OSCC) is one of the most common tumors within the 
oral cavity. Early diagnosis and prognosis tools are urgently needed. This study aimed 
to investigate the activation of the complement system in OSCC patients as potential 
biomarker. Therefore, an innovative complement activation array was developed.
Characterized antibodies detecting the complement activation specific epitopes 
C3a, C5a and sC5b-9 along with control antibodies were implemented into a 
suspension bead array. Human serum from a healthy (n = 46) and OSCC patient 
(n = 57) cohort were used to investigate the role of complement activation in oral 
tumor progression. The novel multiplex assay detected C3a, C5a and sC5b-9 from a 
minimal sample volume of human tears, aqueous humor and blood samples. Limits of 
detection were 0.04 ng/mL for C3a, 0.03 ng/mL for C5a and 18.9 ng/mL for sC5b-9, 
respectively. Biological cut-off levels guaranteed specific detections from serum. The 
mean serum concentration of a healthy control cohort was 680 ng/mL C3a, 70 ng/mL 
C5a and 2247 ng/mL sC5b-9, respectively. The assay showed an intra-assay precision 
of 2.9–6.4% and an inter-assay precision of 9.2–18.2%. 
Increased systemic C5a (p < 0.0001) and sC5b-9 (p = 0.01) concentrations in 
OSCC patients were determined using the validated multiplex complement assay. 
Higher C5a concentrations correlated with tumor differentiation and OSCC extension 
state. Systemic sC5b-9 determination provided a novel biomarker for infiltrating tumor 
growth and C3a levels were associated with local tumor spreading.  
Our study suggests that systemic complement activation levels in OSCC patients 
may be useful to assess disease progression. 
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INTRODUCTION
Oral squamous cell carcinoma (OSCC) is with 90% 
the most prevalent tumor in the head and neck area [1, 2]. 
It belongs to the ten most common tumors worldwide 
with about 300.000 cases every year and with men 
affected twice as often as women [3, 4]. The three most 
common risk factors for developing OSCC are smoking, 
alcohol consumption and human papillomavirus infection 
[3, 5]. Depending on the localization and tumor stage 
the therapy consists of surgical removal, irradiation and 
chemotherapy. In recent years, the therapeutic possibilities 
have been extended via targeted therapies with monoclonal 
antibodies like Cetuximab directed against EGF receptor 
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or Nivolumab, a monoclonal antibody against the receptor 
PD-1 (programmed death) which was shown to prolong 
patient survival with recurring and metastasizing OSCC 
[6–8]. Despite these numerous therapeutic approaches and 
advancements, the mortality rate within the first five years 
is still 50%. One reason for this is missing diagnostic tools 
to detect high-risk lesions in early stages and differentiate 
between harmless and high-risk precursor lesions.
Several recent publications show complement 
activation via three different pathways to be involved during 
the development of OSCC (Figure 1A) [9]. Moreover, 
complement factors have been discussed as biomarkers 
for progression of squamous cell carcinoma [10]. High 
abundance of complement C3, complement factor B (CFB) 
and complement C4B has been demonstrated in the saliva 
of OSCC patients [11], especially in invasive cutaneous 
squamous cell carcinoma (cSCC) and recessive dystrophic 
epidermolysis bullosa–associated cSCCs [12]. Furthermore, 
the complement activation product, C5a, is involved in the 
development of nasopharyngeal carcinoma [13]. Other 
reports also reveal a role for complement proteins during 
ovarian and lung cancer tumor progression [14]. The precise 
role which complement factors play and the mechanisms 
by which they modulate cancer progression is still elusive. 
From a diagnostic point of view, the complement 
system is a challenging group of proteins as the cascade is 
composed of more than 40 proteins, which are concerted 
to activated molecules and form complexes to exert their 
specific functions (Figure 1A) [15]. Complement activation 
is characterized by the generation of anaphylatoxins, C3a 
and C5a, which modulate and attract immune cells via 
their receptors C3aR and C5aR. The larger complement 
cleavage products, e.g. C3b, either bind to the cell surface 
and initiate complement activation or form the terminal 
complement complex (C5b-9), which integrates into the cell 
membrane resulting in cell lysis. If vitronectin binds to this 
complex in fluid-phase, the soluble terminal complement 
complex (sC5b-9) will be formed which is unable to 
integrate into the membrane remaining in plasma (Figure 
1A) [16]. Most of the complement activation diagnostic 
is mainly performed in a single test format either by 
functional analysis using hemolytic assays or by enzyme 
linked immunosorbent assay (ELISA) detecting C3a, C5a 
and other activation products [17]. However, it is desirable 
to monitor complement activation at various levels of 
the cascade reaction (C3a, C5a, sC5b-9) simultaneously 
to verify more specifically the activation status, but also 
to reduce materials used and costs. Different multiplex 
detection platforms had been described in the past, among 
them the suspension bead array technology based on 
differentially fluorescently coded beads is of interest for a 
broad range of use for simultaneous immunoassays (Figure 
1B, 1C) [18]. The assay principle is similar with combined 
sandwich ELISA: Complement activation product detecting 
neo-epitope specific antibodies are immobilized as capture 
antibodies to the color-coded beads. The bead-bound 
analytes are detected via biotinylated antibodies and a 
fluorescent reporter system. The readout is performed by a 
cytometer firstly addressing the fluorescent signature of the 
beads and secondly the intensity of the reporter signal. The 
current work, describes for the first time the implementation 
and validation of the suspension multiplex technology for a 
simultaneous analysis of the complement activation pattern 
of C3a, C5a and C5b-C9 from minimal sample volumes 
of human blood, aqueous humor and tear samples. Using 
the assay we analyzed systemic C3a, C5a and C5b-C9 
concentrations as a biomarker for OSCC tumor extension 
and differentiation state.
RESULTS
Detection of complement activation using a novel 
multiplex suspension assay
With the growing role of the complement system in 
disease progression and novel complement therapeutics in 
clinical use (e.g. Eculizumab) and trials (e.g. Lampalizumab) 
complement monitoring becomes increasingly significant 
[19]. However, complement diagnostic is challenging 
because of multiple complement proteins, their interactions 
and cleavage products.
We established and validated a complement 
activation immunoassay by simultaneous analysis of C3a, 
C5a and sC5b-9 using the Luminex xMap technology and 
specific antibodies. The reactivity of capture and detection 
antibodies for the multiplex complement activation assay 
were evaluated in Western blots against purified complement 
activation products and human serum (Supplementary 
Figure 1). The anti-C3a capture antibody showed a binding 
preference for isolated C3a-fragment (Supplementary 
Figure 1A) and the detection antibody for the C3a 
containing C3 ɑ-chain in human serum (Supplementary 
Figure 1B). Both anti-C5a antibodies detected purified 
C5a in Western blots (Supplementary Figure 1C, 1D). 
C5a was approximately 10-times lower concentrated in 
human serum than C3a (Figure 2B, Figure 6). Therefore, 
the detection limit of the immunoblots were not sufficient 
for C5a analysis from human serum (Supplementary Figure 
1C, 1D). The capture antibody for the sC5b-9 detected C5, 
C6, C7, C8, C9 and vitronectin in purified sC5b-9 complex 
and from human serum (Supplementary Figure 1E). The 
detection antibody showed a binding preference for C6 in 
Western blot (Supplementary Figure 1F).
The characterized capture and detection antibodies 
(Supplementary Figure 1) were implemented into the novel 
multiplex complement activation assay in combination 
with the species-specific negative control antibodies 
(Figure 1B, 1C, Supplementary Table 1). Complement 
activation markers were simultaneously and sensitively 
quantified in the multiplex system (Figure 2A). The LOD 
(limit of detection) was 0.04 ng/mL for C3a detection, 0.03 ng/
mL for C5a detection and 18.96 ng/mL for detection of sC5b-9 
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(Figure 2A, Supplementary Table 1). On average 
0.68 µg/mL C3a, 0.07 µg/mL C5a and 22.47 µg/mL sC5b-
9 were detected in the serum of the healthy control cohort 
(Figure 2B, Supplementary Table 2). The quality of the novel 
multiplex assay was assessed using sample material of an 
international inter-laboratory comparison test (complement 
EQA5, 2015) [19]. We determined C3a within the detection 
range of the reference values, however the concentrations for 
sC5b-9 were at factor 100 higher than the values determined 
by single ELISA and C5a reference levels were not provided 
in the round-robin test [19]. In summary, our novel assay 
allows a reproducible detection of C3a and C5a levels in 
human serum comparable to previously published studies (for 
references see Figure 2B), which determined complement 
activation markers in a comparable range using single 
immunoassays (Figure 2B). 
Multiplex detection assays are characterized by 
simultaneous analysis of multiple ligands in a single tube 
format. Therefore, the specificity and the performance 
of the single and combined assays need to be validated 
separately to assure reliable results independently of the 
sample composition. Bead-specific detection of purified 
antigens was tested in singleplex and multiplex assays 
(Figure 3). The high binding capacities of the anti-C3a, 
anti-C5a- and anti-sC5b-9 beads were shown in a one-
bead assay with a single purified antigen dilution series 
(Figure 3A, 3C, 3E). All three complement activation 
products were detected in dose-dependent logarithmic 
standard curves comprising four decades on a log-scale 
and either ranging from 0.2 to 0.00004 µg/mL for C3a 
(Figure 3A), 0.03–0.00003 µg/mL for C5a (Figure 3C) 
or 67–0.019 µg/mL for sC5b-9 (Figure 3E), respectively. 
The singleplex detection of each antigen was comparable 
with the standard curve performance in the multiplex 
assays, indicating a bead-specific detection (Figure 2A, 
Figure 3A, 3C, 3E). Moreover, unspecific cross-reactivity 
was tested using all five bead regions (Figure 1B, 1C, 
Supplementary Table 1), the three complement detecting 
bead regions and the two negative control bead regions, 
by means of singular antigen dilution series (Figure 3B, 
3D, 3F). Our data showed a specific signal for the antigens 
with all the corresponding beads and did not reveal any 
cross-reactivity with unspecific bead regions or the 
negative control beads (Figure 3B, 3D, 3F). 
Further, we determined the specificity and the 
cut-off levels of our multiplex assay in a more complex 
experimental setting using human sera depleted from 
specific complement factors (C2-C9, properdin and CFH) 
and measured the respective concentrations of C3a, C5a 
and sC5b-9 (Figure 4). The three complement activation 
Figure 1: Principle for multiplex-complement activation assay. (A) The complement system is a part of the innate immunity 
and activated by three different pathways: the classical, the lectin, and the alternative pathway. Activation results in enzymatic cleavage of 
C3 to C3a and C3b. The latter triggers the terminal complement pathway by cleavage of C5 and the formation of the terminal complement 
complex sC5b-C9. The formation of sC5b-C9 and the anaphylatoxins C3a and C5a determines complement activation. (B, C) The detection 
of the complement activation products was performed in multiplex suspension bead array based on the x-MAP technology (Luminex®). 
(B) Activation product specific antibodies were immobilized to distinct fluorescent, magnetic beads to capture either C3a, C5a or sC5b-C9 
from solution, respectively. Antigen specific biotinylated antibodies and phycoerythrin conjugated to streptavidin detected the captured 
activation products simultaneously. (C) False positive signals by cross-reacting human anti-species antibodies and in vitro complement 
activation were excluded by utilizing an appropriate reaction buffer. 
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products were highly specifically detected in human serum 
but not in the respective depleted sera (Figure 4). C3a 
detection was at its lowest level in the C3-depleted serum 
with a concentration of 0.09 µg/mL, which determined our 
cut-off level for the C3a detection assay (Supplementary 
Table 1). The remaining complement depleted sera 
exceeded this cut-off concentration by a factor of 
1.5 (C4-depleted serum) to a factor of 6 (C5-depleted 
serum) (Figure 4A). The physiological serum C3a 
concentration in our healthy probands was at 0.68 µg/
mL rising above the C3a cut off level by a factor of 7 
(Figure 5C, Supplementary Table 2). C5a analysis in 
C5-depleted serum resulted in a cut-off determination 
at 0.01 µg/mL (Supplementary Table 1), which was 
7-times below the physiological C5a concentration in 
our healthy probands and 64 times below the highest 
C5a concentration in C8-depleted serum (Supplementary 
Table 2, Figure 4B, Figure 5D). The lowest detection 
signal of sC5b-9 was observed in C5-depleted serum 
with 2.47 µg/mL. The remaining complement depleted 
sera showed at least 12.5 times the concentration above 
the cut-off (C2-depleted serum) (Figure 4C). The mean 
physiological sC5b-9 serum concentration in our healthy 
control group was at 22.47 µg/mL, which exceeds the 
concentration measured in C5-depleted serum by a factor 
of 9 (Supplementary Table 2, Figure 5E). 
One major advantage of the novel complement 
multiplex assay is the simultaneous quantification of 
three activation markers from a minimal sample volume. 
Therefore, in a proof-of-principle, we analyzed the C3a 
and C5a concentrations in minimal sample volumes 
of human aqueous humor from glaucoma and cataract 
patients (<100 µL) (Figure 5A) as well as in human tears 
(<50 µL) (Figure 5B). The C3a concentrations in aqueous 
humor ranged from 1.4 to 64 ng/mL and overlapped with 
previously described C3a levels in the same sample matrix 
of healthy patients by means of single immunoassays 
[20]. We describe, however, for the first time very low 
C5a concentrations in aqueous humor samples below the 
cut-off levels for serum samples (10 ng/mL) using our 
multiplex assay (Figure 5A). C3a concentrations in tears 
were determined between 4.3–26.5 ng/mL, which was in 
accordance to previous publications (Figure 5B) [21]. A 
simultaneous analysis of C3a with C5a from tears has not 
been described before. We showed for the first time, that 
C5a is a component in tears at a concentration range of 
1.4 ng/mL, which was below the cut-off level for serum 
samples but above the limit of detection (Figure 5B, 
Supplementary Table 1). 
The variability of the 5-plex assay was determined 
at a dilution of 1:50 with a standard quality control serum. 
For each of the activation markers analyzed, the mean intra-
assay precision was between 2.9%–6.4% (Supplementary 
Table 1). The mean inter-assay precision values for all 
analytes were between 9.2% and 18.2% (Supplementary 
Table 1). Similarly, intra- and inter-assay precision values 
for different cytokines in commercial multiplex cytokine 
xMAP-assays were reported [22, 23].
Figure 2: Complement activation markers were simultaneously and sensitively quantified in the multiplex system. (A) 
Serial dilutions of native, human C3a-desArg (black circle), recombinant, human C5a-desArg (black square) and native human sC5b-C9 
(black triangle) depicted different assay performances for the simultaneous analysis of complement activation markers. The target antigens 
were only detected by respective coupled magnetic beads and not by control beads (grey). Limit of detection (orange) and assay cutoffs (red 
square) for each analyte are shown. (B) The concentration range of complement activation markers determined with the novel multiplex 
assay from a human serum pool (black square with dot) corresponded to previously reported ranges for C3a, C5a and sC5b-C9 single 
detection either from plasma (grey), serum (black) or unknown sample matrix (white), respectively [42–62].
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Systemic complement activation in OSCC 
patients assay
C3a, C5a and sC5b-9 concentrations were quantified 
in 103 serum probes using the validated 5-plex assay 
(Supplementary Table 2). Our healthy control cohort 
showed a systemic complement activation concentration 
within a range of 0.2–2.5 µg/mL for C3a (Figure 5C), 0.02–
0.12 µg/mL for C5a (Figure 5D) and 16.3–29.9 µg/mL for 
sC5b-9 (Figure 5E), respectively (Supplementary Table 2).
We compared the levels of C3a, C5a and sC5b-9 in 
serum from OSCC patient cohort (n = 57) to a matched 
healthy control group (n = 46) (Supplementary Table 2). 
Our data clearly showed a significant 60% increase of C5a 
(mean 0.11 µg/mL) and a 12% increase of C5b-9 (mean 
25.22 µg/mL) serum concentrations in OSCC patients 
in contrast to the healthy control group (C5a: mean 0.07 
µg/mL and sC5b-9 mean 22.47 µg/ml) (Figure 5D, 5E). 
However, we did not observe a significant difference in 
C3a concentration in serum from OSCC patients compared 
to healthy controls (Figure 5C).
Furthermore, correlation of our diagnostic analyses 
with retrospective clinical data revealed an association 
between the concentration of specific complement markers 
C3a, C5a and tumor  differentiation (Figure 6A–6C) and 
extension (Figure 6D–6F) in serum from OSCC patients 
Figure 3: Bead-specific detection of purified antigens in singleplex and multiplex assays. (A, B, D, F) Specificity of  C3a-
beads, (C, B, D, F) C5a-beads and (E, B, D, F) sC5b-C9-beads were either analysed in a (A, C, E) one-bead assay with a single antigen 
dilution series or (B, D, F) all five bead regions and a singular antigen dilution series. (B, D, F) All beads showed a specific signal for the 
respective antigen and no cross reactivities. The detection of (A, B) C3a, (C, D) C5a  and (E, F) sC5b-C9 was comparable in the (A, C, E) 
single  and (B, D, F) multiplex assays, indicating a bead-specific detection.  
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compared to healthy controls. The concentrations of all 
three complement activation products were significantly 
elevated in patients with moderately differentiated cells 
(G2-grade tumors) (C3a: p < 0.05, C5a: p < 0.0001, 
sC5b-9: p < 0.05), whereas there was no increase in G1 
(well differentiated), G3 (poorly differentiated) and G4 
(undifferentiated) tumors (Figure 6A–6C). Additionally, 
C5a and sC5b-9 concentrations markedly increased 
dependent on tumor growth comparing serum from 
OSCC patients and healthy controls (Figure 6E, 6F). 
OSCC patients with tumors sizes ranging from <2 cm 
to >4 cm (T1-T3) all harbored significantly higher 
Figure 5: Simultaneous quantification of complement activation markers from aqueous humor, tears and sera of 
OSCC patients and controls. C3a and C5a were either measured in (A) aqueous humor of glaucoma and cataract patients, (B) in tears 
of healthy controls or (C–E)  in sera of OSCC-patients (n = 57) and matched controls (n = 46) using the validated 5-plex immunoassay 
based on luminex technology. (A) The C3a levels of glaucoma and cataract patients did not show any significant difference, but a tendency 
for higher C3a levels in glaucoma patients. C5a concentrations in aqueous humor were below the lower detection limit. (B) Quantification 
of C3a and C5a in tears ranged between 4.4–26 ng/mL for C3a and 0.11–3.3 ng/mL for C5a, respectively. (D, E) C5a and sC5b-C9 
concentrations were significantly increased in OSCC patients compared to the control group. Mean with standard deviations are depicted. 
(**p < 0.01, ****p < 0.0001 two-tailed, unpaired t-test).
Figure 4: The multiplex assay detected complement activation products specifically from complement component-
depleted human sera. (A–C) C3a,  C5a and sC5b-C9 were quantified either in normal human control serum (control) or C2-, C3-, 
C4-, C5-, C6-, C7-, C8-, C9-, properdin-, complement factor H-depleted serum. The lowest concentrations for (A) C3a and (B) C5a were 
observed in C3-depleted or C5-depleted serum, respectively. (C) The terminal complement complex was detected at a reduced level in C5-
depleted serum. We did not observe a detection signal for any of the tested sera on the control beads (data not shown).
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C5a concentrations compared to healthy controls (T1: 
p < 0.005, T2: p < 0.0001, T3: p < 0.05). Moreover, 
patients with infiltrating tumors, regardless of the tumor 
size, also showed markedly higher concentrations of C5a 
(T4: p < 0.0001) (Figure 6E). Interestingly, only serum 
from patients with infiltrating tumors (T4) showed a 
significant difference in sC5b-9 concentration compared 
to the healthy control cohort (Figure 6F).
Furthermore, we were interested as to whether the 
spread of tumor cells to regional lymph nodes was associated 
with changes in C3a, C5a, sC5b-9 concentrations and 
age (Figure 6G–6J). C3a concentration clearly correlated 
with tumor cell spread to local metastases (Figure 6G). 
Metastases in ipsilateral or contralateral lymph nodes (<6 cm, 
N2) revealed increased systemic concentration of C3a 
(1.0 ± 0.26 µg/mL) compared to smaller metastases in 
ipsilateral lymph nodes (<3 cm, N1) (0.7 ± 0.54 µg/mL) and 
no metastasis (N0) (0.9 ± 0.81 µg/mL) (Figure 6G). We did 
not find any correlation between C5a or sC5b-9 and lymph 
node infiltration in serum samples from OSCC patients 
(Figure 6H, 6I). Notably, statistical analysis revealed a strong 
association between the age of OSCC patients and the lymph 
node spread (Figure 6J). Patients with more severe metastasis 
<6 cm in ipsi- and contralateral lymph nodes were on average 
younger (54 ± 6.4 years), compared to patients with less 
severe lymph node spread <3 cm and only ipsilateral and/or 
to patients exposing no regional lymph nodes (67 ± 9 years, 
p < 0.05 and p < 0.01 respectively). However, age did not 
correlate with C3a, C5a or sC5b-9 concentration in serum 
(Figure 6K–6M).
DISCUSSION
The role of the complement system in cancer 
development and progression is a two-sided sword, which 
has been discussed in detail in recent reviews [24–27]. 
On the one hand, there is the anti-tumor activity of the 
complement system mediated by its ability to distinguish 
self from non-self and removing neo-antigen exposing cells 
or killing cells by the membrane-attack complex. On the 
other hand, C5a promotes tumor survival e.g. by increasing 
the infiltration of myeloid-derived suppressor cells and 
reducing the number of CD8+ cytotoxic T cells in the 
microenvironment of the tumor [28]. For further evaluation 
of the dual role of complement and identification of novel 
biomarker in tumor development and progression an 
improvement of complement diagnostic tools was needed 
to cover the multiple functions of the complement system.  
We developed a bead array, which is for the 
first time capable of simultaneous detection of three 
complement activation products not only from a minimal 
buffer volume, but also from human serum, aqueous 
humor and tear fluid. While a variety of complement 
assays work well for single component analysis, many 
diagnostic tests fail when small sample volumes are 
tested for multiple complement proteins. Using the 
multiplex complement assay, we detected C3a and C5a in 
a comparable range as previously described single assays 
(for references see Figure 2B) with a high reproducibility. 
The use of the novel detection method provides a step 
towards standardized array based economized complement 
diagnostic as a tool for disease diagnosis and monitoring 
of complement-targeted therapy [29].
Using our well-validated complement activation 
assay we found a clear evidence of systemic complement 
activation in OSCC patients, as the C5a concentration was 
significantly elevated in OSCC sera compared to controls. 
Furthermore, C3a as well as C5a serum concentrations 
were associated with tumor differentiation, growth and 
extension.
It has not yet been fully elucidated, whether 
complement plays a disease promoting role in OSCC. 
However, our results indicate, that the complement 
system appears to be dysregulated in this cancer. The data 
imply, that a new therapeutic option for OSCC patients 
could be complement-targeting therapeutics, which 
modulate activation or deposition of complement factors 
and influence the tumor microenvironment as well as 
tumorigenic potential [24]. 
It has been discussed before that the chronicity of 
the inflammation affects the role of complement in the 
tumorigenesis, apoptosis, tumor cellular invasion and exerts 
a dual role on tumor growth depending on the character of 
immune response [25, 30]. To evade antibody mediated 
complement dependent cytotoxicity tumor cells can 
adopt diverse strategies. One strategy for OSCC cells and 
other solid tumors like breast and pancreatic tumors is to 
overexpress complement restriction factors (CD46, CD55, 
CD59) in different densities [31]. Gelderman et al. reported 
the deposition of C3 and C5b-9 on cervical carcinoma cells 
and the surrounding stroma. They demonstrated that CD55 
and CD46 were the most potent inhibitors of C3 deposition. 
Moreover, they increased complement activation applying 
specific antibodies against these restriction factors and the 
antibodies could be immunotherapeutic agents to enhance 
the inflammatory reaction at the tumor site [32]. Maehara 
et al. described a mechanism for preventing hepatocellular 
tumor development where AIM (apoptosis inhibitor of 
macrophage) accumulate on the HCC (hepatocellular 
carcinoma) cell surface and activate the complement 
cascade thus inducing necrotic cell death in AIM bound 
HCC cells [33].
However, there is increasing evidence demonstrating 
that several complement factors are produced by tumor cells 
themselves exerting diverse tumor promoting autocrine 
effects. In cSCC (cutaneous squamous cell carcinoma) 
complement factor H and factor H-like protein-1 have 
been identified as potential progression markers as their 
gene expression was upregulated in cSCC cell lines and 
primary cSCC tumors [34]. In patients with ovarian and 
lung cancer autocrine effects of C5aR and C3aR facilitate 
cell proliferation via PI3K/Akt [14]. Silencing PI3K/
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Akt in cancer cells eliminated C5aR and C3aR effects 
in cancer cells. Furthermore, in ovarian and lung cancer 
higher tumoral C3 and/or C5aR mRNA expression 
were associated with decreased overall survival. Cho 
et al. demonstrated complement activation in ovarian 
cancer cells due to an autocrine effect which produces 
complement C3 protein. This process leads to alterations 
in the tumor microenvironment by increasing the number 
of myeloid-derived suppressor cells and reducing the 
number of cytotoxic T cells that infiltrate into the tumor, 
which promotes tumor growth [14]. These results are 
supported by data from Abbriti et al. who analyzed data of 
the current literature of potential meningioma biomarkers 
applying bioinformatic methods [35]. Their approach 
revealed complement factor C3, among 8 other proteins, to 
be particularly related to tumorigenesis of meningioma. In 
addition to that Chen et al. identified among other factors 
complement C3c (C3) to be differentially expressed in 
serum blood samples from 25 OSCC patients compared to 
25 healthy controls via MALDI-TOF mass spectrometry 
[36]. Chemically induced mouse cSCC and 8 cSCC cell 
lines showed significant upregulation of C3 and CFB 
Figure 6: Complement activation markers were associated with tumor differentiation (G), tumor extension (T) and 
lymph node metastases (N). (A–C) The histologic grade (G) describes the cell differentiation in the patients’ tumors/ neoplasms. 
Patients with G2 tumor grading had significantly elevated (A) C3a, as well as (B) C5a and (C) sC5b-9 serum levels compared to the 
control group. (D–F) The T-classification system categorizes the extension of the patients′ primary tumors. (D) There was no relation 
between C3a serum levels and T-classification. (E) All tumor extension classifications (T-classifications) showed a significant increase in 
systemic C5a levels compared to the control group. (F) Invasive growth (T4) is associated with increased sC5b-9 serum levels compared 
to the control, T2 and T3 group. (G–J) The N-classification describes the degree of spread of tumor cells to regional lymph nodes. 
(G) C3a concentration was significantly correlated with tumor spread to lymph nodes. C3a concentration was highest in N2 classified lymph 
node metastases. (H, I) There was no significant correlation between complement markers C5a, sC5b-C9 and lymph node metastases. 
(J) Patients, that presented a N2-tumor, were significantly younger than patients with a N0 or N1 tumor. (K–M) Age was not associated 
with T-classification or correlated with complement activation marker concentration in serum. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001 two-tailed, unpaired t-test).
Oncotarget3009www.impactjournals.com/oncotarget
(complement factor B) gene and protein expression 
compared to benign papilloma and normal human epidermal 
keratinocytes. A knockdown of C3 and CFB expression 
inhibited migration and proliferation of cSCC cells and 
resulted in inhibition of ERK 1/2. Moreover, knockdown 
of C3 and CFB markedly inhibited growth of human 
cSCC xenograft tumors in vivo [12]. Jiang et al. found 
significantly higher serum levels of complement C3 and 
C4 in patients suffering from myeloma bone disease with 
more than three osteolytic lesions compared to patients with 
less lesions. Moreover, C4a serum levels were significantly 
associated with the number of osteolytic lesions. The 
group demonstrated that the levels of C3, C4 and C4a 
were highly related to the severity of bone disease. C3 
and C4 serum levels could also be significantly correlated 
with the percentage of osteoclast precursors and the level 
of bone resorption metabolites (CTX and TRACP-5b) 
[37] Moreover, complement C3 has also been suggested to 
contribute to the secretion of prostaglandin E2 (PGE2) in 
aberrant immune responses during induced inflammation 
in mammals [38]. Furthermore, C5a has been reported to 
be generated in the cancer microenvironment. Cai et al. 
demonstrated the influence of the C5a-C5aR axis on the 
proliferation of human nasopharyngeal carcinoma (NPC) 
in vitro. Here, C5a promoted proliferation of tNPC cells 
via PCAF-mediated STAT3 acetylation [13]. Nitta et al. 
suggest a C5a release from C5 by a cancer cell membrane-
bound serine protease and thus an autocrine activation 
of C5aR-expressing cancer cells (bile duct, colon and 
cholangiocarcinoma cell lines). They showed that this 
activation, besides invasiveness, enhances recruitment 
and induction of myeloid-derived suppressor cells and 
neovascularization [39, 40].
The current work describes for the first time the 
implementation and validation of the suspension multiplex 
technology for a simultaneous analysis of the complement 
activation pattern of C3a, C5a and sC5b-9 from minimal 
sample volumes of human blood, aqueous humor and tear 
samples. Using this highly specific and reproducible assay, 
we identified an increased concentration of systemic C5a 
concentrations as a potential biomarker for OSCC tumor 
extension and differentiation state. We propose multiplex 
complement diagnostic as a feasible tool for biomarker 
analysis in OSCC.
MATERIALS AND METHODS
Patients and clinical data
Blood samples were obtained by venipuncture from 
fasting participants. The study involved adult patients 
examined and treated for a newly diagnosed OSCC (n = 57) 
at the Department of Oral and Maxillofacial Surgery, 
University Hospital of Regensburg, between 2013 and 
2016. All included patients had no previous treatment and 
underwent primary surgical resection of the oral lesion 
and neck dissection based on clinical and radiologic 
findings. The patients had no conditions, which are 
known to be associated with a relevant activation of the 
complement system (e.g. acute infections, asthma, arthritis, 
inflammatory bowel disease) except diabetes or due to 
their history of smoking or alcohol consumption. The 
patient data were obtained prospectively from interview 
of patients or review of medical records. OSCC were 
staged according to the 7th Edition of American Joint 
Committee on Cancer (AJCC) guidelines. Corresponding 
to the tumor patients a matched healthy control cohort 
(n = 46) was defined. Aqueous humor was obtained 
during eye surgery either of open-angle glaucoma 
(n = 13) or cataract (n = 10) patients. Tear fluid was collected 
from healthy controls using Schirmer strips. For protein 
extraction Schirmer strips were incubated in 100 mM 
NH4HCO3 (1 h, room temperature). Subsequently, acetone 
was added (1 h, –20°C). The strips were removed and the 
tubes centrifuged (10 min, 11000 rpm). The supernatant was 
discarded and the remaining protein pellet was air-dried, 
before being dissolved in assay buffer for quantification. The 
protocols were approved by the University of Regensburg 
Ethics Committee (GeschZ 12-101-0070, 13-101-0207, 15-
101-0064, 11-101-0071, 16-299-101) and written informed 
consent was obtained from all participants. 
Proteins and antibodies
The monoclonal mouse antibody against human 
C3a/C3a-desArg (mAb clone 2991, cat. HM2074-IA) 
and the biotinylated monoclonal mouse antibody against 
human C3/C3a (mAb 474-biotin, cat. HM2073-BT) were 
obtained from Hycult Biotech (Beutelsbach, Germany). 
The anti-human C5a/C5a-desArg antibodies (C17/5, cat. 
518202; G25/2-biotin, cat. 518306) were purchased from 
Biozol Diagnostica (Eching, Germany). The polyclonal 
rabbit anti-human sC5b-9 antibody (cat. Ab55811) was 
ordered from Abcam (Cambridge, United Kingdom). The 
goat anti-human C6 antibody (cat. A223) was obtained 
from Complement Technology (Tyler, TX, USA). Goat 
anti-mouse IgG horseradish peroxidase (HRP) (cat. 
115035164), goat anti-rabbit IgG HRP (cat. 111035003), 
rabbit anti-goat IgG HRP (cat. 305035003) as well as 
Streptavidin-HRP (cat. 016030084) were acquired from 
Dianova (Hamburg, Germany).
Western blot analysis 
Purified recombinant human C3a-desArg 
(1 µg, HC2127), C5a-desArg (1 µg, HC2102, Hycult 
Biotech, Beutelsbach, Germany), sC5b-9 (1 µg/0.1 µg, 
A127, Complement Technology, Tyler, TX, USA) or normal 
human serum (20 µg, NHS) were separated under reducing 
and non-reducing conditions in either 10% or 15% SDS-
PAGE and subsequently transferred to polyvinylidene 
difluoride membranes. The membranes were blocked (5% 
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BSA/PBST, 1 h) und then incubated with respective primary 
antibodies in blocking buffer (2 h, room temperature). 
Excess primary antibody was removed by washing the 
membranes with PBST. Secondary peroxidase-conjugated 
anti-mouse, anti-goat, anti-rabbit IgG or Streptavidin-HRP 
were applied in PBST with 2% skim milk. HRP-signal 
was developed with Lumi-Light blotting substrate (Roche 
Diagnostics GmbH, Mannheim, Germany).
Multiplex suspension assay
Bead-conjugation
Capture antibodies were coupled to MagPlex® 
microspheres according to the two-step carbodiimide 
protein coupling protocol of the manufacturer (Luminex 
Corp., Austin, TX, USA). Anti-C3a-desArg (1.7 µg, mAb 
clone 2991, bead region 18), anti-C5a-desArg (25 µg, 
C17/5, bead region 26) and anti-sC5b-9 (75 µg, ab55811, 
bead region 33) were conjugated to 1.25 million beads/
region (Supplementary Table 1). Unspecific species 
control antibodies for mouse IgG (anti-botulinum toxin B 
antibody, 25 µg, bead region 55 [41]) and rabbit IgG (cat. 
B11-034, 75 µg, bead region 78, Gentaur, Kampenhout, 
Belgium) were integrated as specificity controls.
Antibody biotinylation
The goat antibody to human C6 was biotinylated 
according to standard procedures using Biotin-NHS 
(Sigma Aldrich).
Multiplex-assay
The multiplex suspension assay was performed 
as previously described [18]. Briefly, all assays were 
carried out in 96-well black clear flat bottom polystyrene 
microtiter plates (cat.: 3603, Corning Incorporated, New 
York, USA) at room temperature, protected from light 
and shaken at 800 rpm. 2000 antibody-labelled magnetic 
fluorescent microspheres per bead region were incubated 
with 50 µl sample in reaction buffer (human anti-mouse 
antibody diluent [cat. ab19396, Abcam, Cambridge, 
United Kingdom], 0.1 mg/mL Nafamostat Mesilate, 0.01 
M EDTA) to inhibit in vitro complement activation and 
avoid anti-species interactions (2 h). A mixture of serial 
1:3 diluted human native C3a-desArg (197.5–0.001 ng/mL, 
cat. HC2127, Hycult Biotech, Beutelsbach, Germany), 
human recombinant C5a-desArg (28.1–0.004 ng/mL, 
Hycult Biotech, Beutelsbach, Germany) and human native 
sC5b-9 (66.6–0.0004 µg/mL, cat. A127, Complement 
Technology, Tyler, TX, USA) were used as standard curve. 
Human serum (1:50- 1:350), aqueous humor (concentrated) 
and tear proteins (0.5–8 mg/mL) were added as sample 
material. A cocktail of titrated biotinylated detection 
antibodies was incubated with the washed bead mixtures 
(1 h, Supplementary Table 1). Streptavidin-R-phycoerythrin 
(SA-PE) PJRS14 (1 µg/mL in 1% BSA/PBS, Hayward, 
California, USA) was added for detection (30 min). 
Following washing, the beads were resuspended in 125 µL 
1% BSA/PBS and the fluorescent signature of the beads as 
well as the corresponding PE-reporter signal was recorded 
using the Luminex Magpix system, in combination with 
the Bio-Plex Manager software (Bio-Rad Laboratories, 
Munich, Germany).
Assay validation
Limit of detection (LOD) was calculated by adding 
three standard deviations to the mean of the mean fluorescence 
intensities (MFI) of sixteen blanks. The lower and the upper 
plateaus as well as the half maximal concentrations (IC50) 
were determined from sigmoidal fitted standard curves with 
a variable slope (Graphpad prism). To assess within- (intra) 
and between- (inter) run precision, we analysed the quality 
control (standardized NHS 1:50) in the linear concentration 
range 6-times on the same plate and same day (intra) or on 
different plates and different days (inter). We calculated the 
coefficient of variation = [(standard deviation/mean) * 100)]. 
Specificity was determined by measuring cross-reactivity to 
complement factor depleted human sera (1:50, Complement 
technology, Tyler, TX, USA). The multiplex assay cutoffs 
were determined as complement concentration in the 
respective complement depleted sera.
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